Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development of Emulgel Delivery of Mupirocin for Treatment of Skin Infection

Author(s): Swati C. Jagdale* and Payal V. Kothekar

Volume 15, Issue 2, 2020

Page: [137 - 156] Pages: 20

DOI: 10.2174/1386207323999200819153404

Price: $65

Abstract

Aim: To design controlled release topical delivery of mupirocin for the treatment of skin infection.

Background: Mupirocin is an antibacterial drug. Mupirocin works to kill the bacteria, which include strains of Staphylococcus aureus and Streptococcus pyogenes. It is also used for the treatment of inflammation of a hair follicle. The half-life of mupirocin is only 20-40 min. It has very slight solubility in water. Patent literature had shown work on ointment, antibiotic composition, nasal and topical composition. Emulgel is a duel control release system for the topical delivery of hydrophobic drugs.

Objective: The objective was to formulate emulgel with controlled delivery of mupirocin using Sepineo P 600.

Methods: Soya oil, tween 80 and polyethylene glycol 400 (Oil:Surfactant:Cosurfactant) were used for emulsion formulation. Emulgel was optimized by 32 factorial design. Sepineo P 600 and hydroxy propyl methyl cellulose K4M were used as independent variables. Drug excipient compatibility analysis was carried out by FTIR, UV and DSC spectra. Emulgel was evaluated for its physical characterization, in vitro release, ex vivo release, antimicrobial and anti-inflammatory study.

Results: DSC, UV and FTIR analysis confirmed drug excipient compatibility. FE SEM showed a size range between 228-255 nm. Zeta potential was found to be -25.1 mV, which showed good stability of the emulsion. Design expert software showed F2 as an optimized batch. Release studies indicated that the controlled release of drugs forms Sepineo P 600 gel due to its higher gelling capacity. Batch F2 showed comparable results with marketed formulation against Staphylococcus aureus. For batch F2, 40 μg/ml was the minimal inhibitory concentration.

Conclusion: Antimicrobial and anti-inflammatory study proved successful development of stably controlled release mupirocin emulgel.

Keywords: Topical, delivery, emulgel, mupirocin, skin infection, sepineo P 600.

« Previous Next »
Graphical Abstract

[1]
Mehetre GS, Dudhal SC, Jadhav SR, Pingle RM. Emulgel: an overview in topical drug delivery system. World J Pharm Sci 2018; 7(9): 483-94.
[2]
Brown TL, Petrovski S, Chan HT, Angove MJ, Tucci J. Semi-Solid and solid dosage forms for the delivery of phage therapy to epithelia. Pharmaceuticals (Basel) 2018; 11(1)E26
[http://dx.doi.org/10.3390/ph11010026] [PMID: 29495355]
[3]
Joseph J, Daisy PA, George BJ, Praveen RR, Thomas N, Carla B. Emulgel: a novel trend in topical drug delivery system. WJPMR 2017; 3(4): 35-9.
[4]
Supriya U, Seema CB, Preeti K. Emulgel: a boon for dermatological diseases. Int J Pharm Res Allied Sci 2014; 3(4): 1-9.
[5]
Phad AR, Dilip NT, Ganapathy RS. Emulgel: a comprehensive review for topical delivery of hydrophobic drugs. Asian J Pharm 2018; 12(2): S382.
[6]
Manuel SG. Skin-care preparations containing mupirocin and betamethasone dipropionate. EP1932525B1. 2005.
[7]
Ojer CG, Allo BG, Fernández FP, de Miguel CY. Pharmaceutical topical composition of mupirocin. EP2629756B1 . 2014.
[8]
Lavon I, Zeevi A, Cherkez S, Arkin M, Kaspi J, Abu- Gnim C, Racchav Y. Pharmaceutical compositions containing mupirocin. US6489358B2. 2002.
[9]
Dhuppad UR, Khachane VS, Bhamre NB, Dongre P, Sharma AD. Topical composition containing the combination of mupirocin and beclomethasone. WO2009047788A2. 2009.
[10]
Zimmerman HL. Pharmaceutical and veterniary compositions of mupirocin and methods for their preparation.US6025389 . 2000.
[11]
Banov D. Mupirocin antibiotic composition. US2014371305A1. 2018.
[12]
Information for Mupirocin at Drug bank. Available from: . https://www.drugbank.ca/drugs/DB00410(Accessed on: Apr 9,2018.
[13]
Information for Mupirocin Dailymed. Available from:. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=mupirocin ( Accessed on: Apr 27, 2018.
[14]
Putney I. Mupirocin - Putney, Inc.: Veterinary Package Insert. Available from:. https://vetlabel.com/lib/vet/meds/mupirocin-2/(Accessed on: Apr 27, 2018.
[15]
Khalil EA, Majid SA, Suaifan GA, Al-Akayleh FT, Sallam AS. Physicochemical characterization of emulgel formulated with Sepineo P 600, Sepineo SE 68 and cosolvent mixtures. Pharm Dev Technol 2016; 21(5): 519-27.
[http://dx.doi.org/10.3109/10837450.2015.1022789] [PMID: 25757641]
[16]
Jagdale S, Pawar S. Gellified emulsion of ofloxacin for transdermal drug delivery system. Adv Pharm Bull 2017; 7(2): 229-39.
[http://dx.doi.org/10.15171/apb.2017.028] [PMID: 28761825]
[17]
Kinnera V, Shanmugam V. Formulation and evaluation of mupirocin encapsulated sodium alginate microspheres for controlled release drug delivery. Int J Inno Pharm Res 2015; 6(2): 478-84.
[18]
López-Cervantes M, Escobar-Chávez JJ, Casas-Alancaster N, Quintanar-Guerrero D, Ganem-Quintanar A. Development and characterization of a transdermal patch and an emulgel containing kanamycin intended to be used in the treatment of mycetoma caused by Actinomadura madurae. Drug Dev Ind Pharm 2009; 35(12): 1511-21.
[http://dx.doi.org/10.3109/03639040903037215] [PMID: 19929211]
[19]
Yang C, Shen Y, Wang J, Ouahab A, Zhang T, Tu J. Cationic polymer-based micro-emulgel with self-preserving ability for transdermal delivery of diclofenac sodium. Drug Deliv 2015; 22(6): 814-22.
[http://dx.doi.org/10.3109/10717544.2014.898111] [PMID: 24724988]
[20]
Jagdale S, Brahmane S, Chabukswar A. Optimization of microemulgel for tizanidine hydrochloride. Antiinflamm Antiallergy Agents Med Chem 2020; 19(2): 158-79.
[http://dx.doi.org/10.2174/1871523018666190308123100] [PMID: 30854978]
[21]
Jeengar MK, Rompicharla SV, Shrivastava S, Chella N, Shastri NR, Naidu VG, et al. Emu oil based nano-emulgel for topical delivery of curcumin. Int J Pharm 2016; 506(1-2): 222-36.
[http://dx.doi.org/10.1016/j.ijpharm.2016.04.052] [PMID: 27109049]
[22]
Jagdale S, Chaudhari B. Optimization of microemulsion based transdermal gel of triamcinolone. Recent Pat Anti-Infect Drug Discov 2017; 12(1): 61-78.
[http://dx.doi.org/10.2174/1574891X12666170426092911] [PMID: 28506203]
[23]
Deepak SN, Hari BV. Optimization, development and evaluation of microemulsion for the release of combination of guaifenesin and phenylephrine. J Appl Pharm Sci 2013; 3(9): 48-56.
[http://dx.doi.org/10.7324/JAPS.2013.3909]
[24]
Anjana MN, Joseph J, Nair SC. Solubility and bioavailability enhancement of albendazole by complexing with hydroxy propyl β cyclodextrin. J Chem Pharm Res 2015; 7(4): 1131-41.
[25]
Varma VNSK, Maheshwari PV, Navya M, Reddy SC, Shivakumar HG, Gowda DV. Calcipotriol delivery into the skin as emulgel for effective permeation. Saudi Pharm J 2014; 22(6): 591-9.
[http://dx.doi.org/10.1016/j.jsps.2014.02.007] [PMID: 25561873]
[26]
Ahmad J, Gautam A, Komath S, Bano M, Garg A, Jain K. Topical nano-emulgel for skin disorders: formulation approach and characterization. Recent Pat Anti-Infect Drug Discov 2019; 14(1): 36-48.
[http://dx.doi.org/10.2174/1574891X14666181129115213] [PMID: 30488798]
[27]
Pranali S, Charushila S, Sayali C, Namrata M. Design and characterisation of emulgel of an antifungal drug. J Pharm Sci Res 2019; 11(6): 2357-61.
[28]
Patel H, Panchal M, Shah S, Vadalia KR. Formulation and evaluation of transdermal gel of sildenafil citrate. Int J Pharm Res Allied Sci 2012; 1(3): 103-18.
[29]
Costa P, Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001; 13(2): 123-33.
[http://dx.doi.org/10.1016/S0928-0987(01)00095-1] [PMID: 11297896]
[30]
Marwaha TK. Formulation design and evaluation of herbal anti psoriatic emulgel. J Pharm Sci Inno 2013; 2(3): 30-42.
[http://dx.doi.org/10.7897/2277-4572.02334]
[31]
Sritharadol R, Nakpheng T, Wan Sia Heng P, Srichana T. Development of a topical mupirocin spray for antibacterial and wound-healing applications. Drug Dev Ind Pharm 2017; 43(10): 1715-28.
[http://dx.doi.org/10.1080/03639045.2017.1339077] [PMID: 28581830]
[32]
Shravan KN, Kishore G, Siva G, Sindhu ES. In-vitro anti-inflammatory and anti-arthritic activity of leaves of Physalis angulata L. Int J Pharm Ind Res 2011; 01(03): 211-3.
[33]
Jahan F, Lawrence R, Kumar V, Junaid M. Evaluation of antimicrobial activity of plant extracts on antibiotic susceptible and resistant Staphylococcus aureus strains. J Chem Pharm Res 2011; 3(4): 777-89.
[34]
Leo A, Hansch C, Elkins D. Partition coefficients and their uses. Chem Rev 1971; 71(6): 525-616.
[http://dx.doi.org/10.1021/cr60274a001]
[35]
Panda V, Boddu S, Rathod S. Simultaneous estimation and validation of mupirocin and satranidazole by UV spectrophotometry. Indo Am J Pharm Res 2016; 6(3): 4599-604.
[36]
Ghulam Nabi Azad Indian Pharmacopoeia. 7th ed. Indian Pharmacopoeia Commission (IPC) publisher: India. 2014.

Rights & Permissions Print Cite
Article Metrics
28
© 2024 Bentham Science Publishers | Privacy Policy